Interstitial Cystitis Drugs Market Size & Share, by Type [Nonsteroidal Anti-inflammatory Drugs, Tricyclic Antidepressants, Antihistamines, Pentosan Polysulfate Sodium (Elmiron); Dimethyl Sulfoxide (DMSO); Hyaluronic Acid (Cystistat)]; Route of Administration (Oral, Parenteral); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5257
  • Published Date: Sep 25, 2023
  • Report Format: PDF, PPT

Companies Dominating the Interstitial Cystitis Drug Landscape

top-features-companies
    • Pfizer Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Johnson & Johnson
    •  Kyorin Pharmaceutical Co Ltd.
    • UCB Pharma
    • Bayer AG
    • Eli Lilly and Company
    • Lipella Pharmaceuticals
    • Seikagaku Corporation
    • Grünenthal

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • The Ministry of Health, Labor and Welfare granted Kyorin Pharmaceutical Co., Ltd. a license. marketing “Zymso 50% Intravenous Solution” for interstitial cystitis  in Japan. Kyorin Pharmaceutical Company Limited is a wholly owned subsidiary of KYORIN Holdings, Inc.
     
  • Kyorin Pharmaceutical Company Limited a wholly owned subsidiary of KYORIN Holdings, Inc., has launched the interstitial cystitis product "Zymso® Intravesical Solution 50%"

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5257
  • Published Date: Sep 25, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The growing prevalence of interstitial cystitis and growing innovation and product launches are some of the major factors anticipated to drive the growth of the interstitial cystitis drug market.

The market is anticipated to attain a CAGR of ~5% over the forecast period, i.e., 2024 – 2036.

The major players in the market are of Johnson & Johnson, Kyorin Pharmaceutical Co Ltd., UCB Pharma, Bayer AG, Eli Lilly and Company, Lipella Pharmaceuticals and others.

The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying